ARTHQ (Arch Therapeutics) Total Equity: $-12.56 Mil (As of Jun. 2024)


ARTHQ Arch Therapeutics Inc ARTHQ
12 GF Score
Price $0.00
View Full Analysis

What is Arch Therapeutics Total Equity?

Arch Therapeutics ARTHQ -99.00% 12 Total Equity is $-12.56 Mil as of Jun. 2024. GuruFocus rates ARTHQ with a GF Score™ of 12/100.

Arch Therapeutics's total equity for the quarter that ended in Jun. 2024 was $-12.56 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Arch Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Total Equity Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.81 -1.50 -1.03 -4.19 -7.51

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.02 -7.51 -9.58 -10.88 -12.56
ARTHQ
12GF Score
Arch Therapeutics Inc ARTHQ
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Arch Therapeutics's Total Equity for the fiscal year that ended in Sep. 2023 is calculated as

Total Equity=Total Assets(Q: Sep. 2023 )-Total Liabilities(Q: Sep. 2023 )
=1.958-9.466
=-7.51

Arch Therapeutics's Total Equity for the quarter that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=1.398-13.958
=-12.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-12.56 Mil mean?
Arch Therapeutics (ARTHQ) has a Total Equity of $-12.56 Mil as of Jun. 2024. The total amount of equity as record on a company's balance sheet. View historical data for Arch Therapeutics and its competitors.
Is Arch Therapeutics' Total Equity too high?
Arch Therapeutics' current Total Equity is $-12.56 Mil. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' Total Equity compare to GRTSQ and MTEM?
Arch Therapeutics' Total Equity of $-12.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Arch Therapeutics and its competitors. Arch Therapeutics's current Total Equity is $-12.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current Total Equity of $-12.56 Mil. The current Total Equity is $-12.56 Mil. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current Total Equity is $-12.56 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for ARTHQ

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price